Biological perspectives: Atypical antipsychotic drugs: Part 1

Perspectives in Psychiatric Care

Volumn 36, Issue 3, 2000, Pages 101-104

  Keltner, Norman L ^a   Coffeen, Heather ^a   Johnson, Janna E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Atypical antipsychotics; Clozapine; Risperidone

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; RISPERIDONE;

BRAIN; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; HUMAN; NURSING; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, NEUROTRANSMITTER; RISPERIDONE;

EID: 0034236530     PISSN: 00315990     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2000.tb00700.x     Document Type: Review

References (36)

1. Addington D.E., Jones, B., & Bloom, D. (1993). Reduction of hospital days in chronic schizophrenia patients treated with risperidone: A retrospective study. Clinical Therapeutics, 15, 917-926.
2. Applegate, M. (1999). Cytochrome P450 isoenzymes: Nursing considerations. Journal of the American Psychiatric Nurses Association, 5(1), 15-22.
3. Awouters, F., Niemegeers, C.J., Megens, A.A., & Janssen, R.A. (1990). Functional interaction between serotinin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine. Journal of Pharmacology and Experimental Therapeutics, 254, 945-951.
4. Bezchlibnyk-Butler, K.Z., & Jeffries, J.J. (1997). Clinincal handbook of psychotropic drugs. Seattle: Hogrefe & Huber.
5. Bleich, A., Brown, S.L., Kahn, R., & Van Praag, H.M. (1988). The role of serotonin in schizophrenia. Schizophrenia Bulletin, 14, 297-315.
6. Blin, O. (1999). A comparative review of new antipsychotics. Canadian Journal of Psychiatry, 44, 235-244.
7. Borison, R.L., Pathiraja, A.P., Diamond, B.I., & Meibach, R.C. (1992). Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacological Bulletin, 28, 213-218.
8. Chong, S-A., Remington, G.J., & Bezchlibnyk-Butler, K.Z. (2000). Effect of clozapine on polypharmacy. Psychiatric Services, 51, 250-252.
9. Chouinard, G., & Arnott, W. (1993). Clinical review of risperidone. Canadian Journal of Psychiatry, 38(Suppl.3), S89-S95.
10. Claus, A., Bollen, J., De Cuyper, H., Eneman, M., Malfroid, M., Peuskens, J., & Heylen, S. (1992). Risperidone vs. haloperidol in the treatment of chronic schizophrenia inpatients: A multicenter double-blind comparative study. Acta Psychiatrica Scandanavica, 85, 295-305.
11. Ereshefsky, L., & Lacombe, S. (1993). Pharmacological profile of risperidone. Canadian Journal of Psychiatry, 38(Suppl.3), S80-S88.
12. Fleischhacker, W.W., & Hummer, M. (1997). Drug treatment of schizophrenia in the 1990s: Achievements and future possibilities in optimizing outcomes. Drugs, 53, 915-929.
13. Friedman, J. (1998). Olanzapine in the treatment of dopaminometic psychosis in patients with Parkinson's disease. Neurology, 50, 1195-1196.
14. Gutierrez-Esteinou, R., & Grebb, J.A. (1997). Risperidone: An analysis of the first three years in general use. International Clinical Psychopharmacology, 12(Suppl.4), S3-S10.
15. Hegarty, J.D., Baldessarini, R.J., Tohen, M., Waternaux, C., & Oepen, G. (1994). One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409-1416.
16. Hertel, P., Fagerquist, M.V., & Svensson, T.H. (1999). Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha-2 adrenoreceptor blockade. Science, 286, 105-107.
17. Idanpaan-Heikkila, J., Alhava, E., Olkinuora, M., & Palva, I. (1975). Clozapine and agranulocytosis (letter). Lancet, 2(7935), 611.
18. Jaretz, N., Flowers, E., & Millsap, L. (1992). Clozapine: Nursing care considerations. Perspectives in Psychiatric Care, 28(3), 19-24.
19. Jibson, M.D., & Tandon, R. (1998). New atypical antipsychotic medications. Journal of Psychiatric Research, 32, 215-228.
20. Keltner, N.L. (1991). Clozapine: Miracle or mirage? Perspectives in Psychiatric Care, 27(1), 35-36.
21. Keltner, N.L. (1995). Risperidone: The search for a better antipsychotic. Perspectives in Psychiatric Care, 31, 30-33.
22. Keltner, N.L. (2000a). Mechanisms of antidepressant action: In brief. Perspectives in Psychiatric Care, 36, 69-71.
23. Keltner, N.L. (2000b). Neuroreceptor function and psychopharmacological response. Issues in Mental Health Nursing, 21, 31-50.
24. Lam, W.F.L. (1999). Clozapine and fluvoxamine. Psychopharmacology Update, 10(2), 2.
25. Land, W., & Salzman, C. (1994). Risperidone: A novel antipsychotic medication. Hospital and Community Psychiatry, 45, 434-435.
26. Lieberman, J.A., & Tasman, A. (2000). Psychiatric drugs. Philadelphia: Saunders.
27. Littrell, K., & Magill, A.M. (1993). The effect of clozapine on pre-existing tardive dyskinesia. Journal of Psychosocial Nursing and Mental Health Services, 31(9), 14-18.
28. Marder, S.R. (1997). Risperidone (Risperdal). The Decade of the Brain, 8(3), 5-7.
29. Marder, S.R., & Meibach, R.C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
30. McCombs, J.S., Nichol, M.B., Johnstone, B.M., Stimmel, G.L., Shi, J., & Smith, R. (2000). Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatric Services, 51, 525-527.
31. Mok, H., & Yatham, L.N. (1994). Response to clozapine as a predictor of risperidone response in schizophrenia (letter). American Journal of Psychiatry, 151, 1393-1394.
32. Oyemumi, L.K. (1999). Does lithium have a role in the prevention and management of clozapine-induced granulocytopenia? Psychiatric Annals, 29, 597-603.
33. Sachs, G.S. (1999, July). Sanity versus vanity - Balancing problem weight gain and the benefits of psychotropic drugs. Therapeutic Advances in Psychoses, 5-6.
34. Safferman, A., Lieberman, J.A., Kane, J.M., Szymanski, S., & Kinon, B. (1991). Update on clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17, 247-261.
35. Sherman, C. (1999). Atypical antipsychotics cut schizophrenia relapse risk. Clinical Psychiatry News, 27(6), 23.
36. Spivak, B., Mester, R., Abesgaus, J., Wittenberg, N., Adlersberg, S., Gonen, N., & Weizman, A. (1997). Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. Journal of Clinical Psychiatry, 58, 318-322.